secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0001558370-23-010763
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris stockholders approve doubling of authorized shares to 200M at annual meeting
--------------------------------------------------------------------------------

- Amendment to authorized common stock from 100M to 200M shares approved: 60.7M for, 547K against, 3.4M abstain.
- All three director nominees elected: Mehra 58.4M for, Powell 39.3M for, Gowen 57.3M for (Powell had 20.6M withheld).
- Advisory say-on-pay approved: 58.6M for, 1.2M against, 28K abstain.
- Ratification of PwC as auditor approved: 64.7M for, 16K against, 13K abstain.
- Meeting turnout: 91.56% of 70.7M outstanding shares represented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023010763/0001558370-23-010763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023010763/acrs-20230601x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-010763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer